Diabetes Research and Clinical Practice
Volume 74, Issue 2, Supplement , Pages S3-S8 , 30 November 2006

Lipotoxicity versus adipotoxicity—The deleterious effects of adipose tissue on beta cells in the pathogenesis of type 2 diabetes

References 

  1. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann. Intern. Med. 1995;122:481–486
  2. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Beta-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J. Clin. Endocrinol. Metab. 2005;90:493–500
  3. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52:102–110
  4. Deng S, Vatamaniuk M, Huang X, Doliba N, Lian MM, Frank A, et al. Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects. Diabetes. 2004;53:624–632
  5. Paolisso G, Tataranni PA, Foley JE, Bogardus C, Howard BV, Ravussin E. A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of niddm. Diabetologia. 1995;38:1213–1217
  6. Unger RH, Zhou YT, Orci L. Regulation of fatty acid homeostasis in cells: novel role of leptin. Proc. Natl. Acad. Sci. U.S.A. 1999;96:2327–2332
  7. Cnop M, Welsh N, Jonas JC, Jorns A, Lenzen S, Eizirik DL. Mechanisms of pancreatic {beta}-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes. 2005;54(Suppl. 2):S97–S107
  8. Eizirik DL, Flodstrom M, Karlsen AE, Welsh N. The harmony of the spheres: inducible nitric oxide synthase and related genes in pancreatic beta cells. Diabetologia. 1996;39:875–890
  9. Yamashita T, Eto K, Okazaki Y, Yamashita S, Yamauchi T, Sekine N, et al. Role of uncoupling protein-2 up-regulation and triglyceride accumulation in impaired glucose-stimulated insulin secretion in a beta-cell lipotoxicity model overexpressing sterol regulatory element-binding protein-1c. Endocrinology. 2004;145:3566–3577
  10. Medvedev AV, Snedden SK, Raimbault S, Ricquier D, Collins S. Transcriptional regulation of the mouse uncoupling protein-2 gene. Double e-box motif is required for peroxisome proliferator-activated receptor-gamma-dependent activation. J. Biol. Chem. 2001;276:10817–10823
  11. Chan CB, De Leo D, Joseph JW, McQuaid TS, Ha XF, Xu F, et al. Increased uncoupling protein-2 levels in beta-cells are associated with impaired glucose-stimulated insulin secretion: mechanism of action. Diabetes. 2001;50:1302–1310
  12. Langin D. Diabetes, insulin secretion, and the pancreatic beta-cell mitochondrion. N. Engl. J. Med. 2001;345:1772–1774
  13. Zhang CY, Baffy G, Perret P, Krauss S, Peroni O, Grujic D, et al. Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, beta cell dysfunction, and type 2 diabetes. Cell. 2001;105:745–755
  14. Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: molecular links between obesity and atheroslcerosis. Am. J. Physiol. Heart Circ. Physiol. 2005;288:H2031–H2041
  15. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J. Allergy Clin. Immunol. 2005;115:911–919(quiz 920)
  16. Fasshauer M, Paschke R. Regulation of adipocytokines and insulin resistance. Diabetologia. 2003;46:1594–1603
  17. Hotamisligil GS, Johnson RS, Distel RJ, Ellis R, Papaioannou VE, Spiegelman BM. Uncoupling of obesity from insulin resistance through a targeted mutation in ap2, the adipocyte fatty acid binding protein. Science. 1996;274:1377–1379
  18. Park HS, Park JY, Yu R. Relationship of obesity and visceral adiposity with serum concentrations of crp, tnf-alpha and il-6. Diabetes Res. Clin. Pract. 2005;69:29–35
  19. Pedersen M, Bruunsgaard H, Weis N, Hendel HW, Andreassen BU, Eldrup E, et al. Circulating levels of tnf-alpha and il-6-relation to truncal fat mass and muscle mass in healthy elderly individuals and in patients with type-2 diabetes. Mech. Ageing Dev. 2003;124:495–502
  20. Hotamisligil GS, Budavari A, Murray D, Spiegelman BM. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J. Clin. Invest. 1994;94:1543–1549
  21. Zhang S, Kim KH. Tnf-alpha inhibits glucose-induced insulin secretion in a pancreatic beta-cell line (ins-1). FEBS Lett. 1995;377:237–239
  22. Campbell IL, Iscaro A, Harrison LC. Ifn-gamma and tumor necrosis factor-alpha. Cytotoxicity to murine islets of langerhans. J. Immunol. 1988;141:2325–2329
  23. Sekine N, Ishikawa T, Okazaki T, Hayashi M, Wollheim CB, Fujita T. Synergistic activation of nf-kappab and inducible isoform of nitric oxide synthase induction by interferon-gamma and tumor necrosis factor-alpha in ins-1 cells. J. Cell. Physiol. 2000;184:46–57
  24. Cetkovic-Cvrlje M, Eizirik DL. Tnf-alpha and ifn-gamma potentiate the deleterious effects of il-1 beta on mouse pancreatic islets mainly via generation of nitric oxide. Cytokine. 1994;6:399–406
  25. Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R. Effects of an engineered human anti-tnf-alpha antibody (cdp571) on insulin sensitivity and glycemic control in patients with niddm. Diabetes. 1996;45:881–885
  26. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J. Clin. Endocrinol. Metab. 1998;83:847–850
  27. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology. 2004;145:2273–2282
  28. Lagathu C, Bastard JP, Auclair M, Maachi M, Capeau J, Caron M. Chronic interleukin-6 (il-6) treatment increased il-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem. Biophys. Res. Commun. 2003;311:372–379
  29. Testa R, Olivieri F, Bonfigli AR, Sirolla C, Boemi M, Marchegiani F, et al. Interleukin-6-174 g>c polymorphism affects the association between il-6 plasma levels and insulin resistance in type 2 diabetic patients. Diabetes Res. Clin. Pract. 2006;71:299–305
  30. Campbell IL, Cutri A, Wilson A, Harrison LC. Evidence for il-6 production by and effects on the pancreatic beta-cell. J. Immunol. 1989;143:1188–1191
  31. Choi SE, Choi KM, Yoon IH, Shin JY, Kim JS, Park WY, et al. Il-6 protects pancreatic islet beta cells from pro-inflammatory cytokines-induced cell death and functional impairment in vitro and in vivo. Transpl. Immunol. 2004;13:43–53
  32. Otero M, Lago R, Lago F, Casanueva FF, Dieguez C, Gomez-Reino JJ, et al. Leptin, from fat to inflammation: old questions and new insights. FEBS Lett. 2005;579:295–301
  33. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N. Engl. J. Med. 1996;334:292–295
  34. Elmquist JK. Hypothalamic pathways underlying the endocrine, autonomic, and behavioral effects of leptin. Physiol. Behav. 2001;74:703–708
  35. Petersen KF, Oral EA, Dufour S, Befroy D, Ariyan C, Yu C, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J. Clin. Invest. 2002;109:1345–1350
  36. Fischer S, Hanefeld M, Haffner SM, Fusch C, Schwanebeck U, Kohler C, et al. Insulin-resistant patients with type 2 diabetes mellitus have higher serum leptin levels independently of body fat mass. Acta Diabetol. 2002;39:105–110
  37. Widjaja A, Stratton IM, Horn R, Holman RR, Turner R, Brabant G. Ukpds 20: plasma leptin, obesity, and plasma insulin in type 2 diabetic subjects. J. Clin. Endocrinol. Metab. 1997;82:654–657
  38. Tatti P, Masselli L, Buonanno A, Di Mauro P, Strollo F. Leptin levels in diabetic and nondiabetic subjects. Endocrine. 2001;15:305–308
  39. Boden G, Chen X, Kolaczynski JW, Polansky M. Effects of prolonged hyperinsulinemia on serum leptin in normal human subjects. J. Clin. Invest. 1997;100:1107–1113
  40. Seufert J. Leptin effects on pancreatic beta-cell gene expression and function. Diabetes. 2004;53(Suppl. 1):S152–S158
  41. Maedler K, Sergeev P, Ehses JA, Mathe Z, Bosco D, Berney T, et al. Leptin modulates beta cell expression of il-1 receptor antagonist and release of il-1beta in human islets. Proc. Natl. Acad. Sci. U.S.A. 2004;101:8138–8143
  42. Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, et al. Adiponectin and development of type 2 diabetes in the pima indian population. Lancet. 2002;360:57–58
  43. Putz DM, Goldner WS, Bar RS, Haynes WG, Sivitz WI. Adiponectin and c-reactive protein in obesity, type 2 diabetes, and monodrug therapy. Metabolism. 2004;53:1454–1461
  44. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr. Rev. 2005;26:439–451
  45. Rakatzi I, Mueller H, Ritzeler O, Tennagels N, Eckel J. Adiponectin counteracts cytokine- and fatty acid-induced apoptosis in the pancreatic beta-cell line ins-1. Diabetologia. 2004;47:249–258
  46. Winzell MS, Nogueiras R, Dieguez C, Ahren B. Dual action of adiponectin on insulin secretion in insulin-resistant mice. Biochem. Biophys. Res. Commun. 2004;321:154–160
  47. Staiger K, Stefan N, Staiger H, Brendel MD, Brandhorst D, Bretzel RG, et al. Adiponectin is functionally active in human islets but does not affect insulin secretory function or beta-cell lipoapoptosis. J. Clin. Endocrinol. Metab. 2005;90:6707–6713
  48. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409:307–312
  49. Fain JN, Cheema PS, Bahouth SW, Lloyd Hiler M. Resistin release by human adipose tissue explants in primary culture. Biochem. Biophys. Res. Commun. 2003;300:674–678
  50. Curat CA, Wegner V, Sengenes C, Miranville A, Tonus C, Busse R, et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia. 2006;49:744–747
  51. Beltowski J. Adiponectin and resistin—new hormones of white adipose tissue. Med. Sci. Monit. 2003;9:RA55–RA61
  52. Utzschneider KM, Carr DB, Tong J, Wallace TM, Hull RL, Zraika S, et al. Resistin is not associated with insulin sensitivity or the metabolic syndrome in humans. Diabetologia. 2005;48:2330–2333
  53. Minn AH, Patterson NB, Pack S, Hoffmann SC, Gavrilova O, Vinson C, et al. Resistin is expressed in pancreatic islets. Biochem. Biophys. Res. Commun. 2003;310:641–645
  54. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307:426–430
  55. Sethi JK, Vidal-Puig A. Visfatin: the missing link between intra-abdominal obesity and diabetes?. Trends Mol. Med. 2005;11:344–347
  56. Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, et al. Elevated plasma level of visfatin/pre-b cell colony-enhancing factor in patients with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 2006;91:295–299
  57. Krzyzanowska K, Krugluger W, Mittermayer F, Rahman R, Haider D, Shnawa N, et al. Increased visfatin concentrations in women with gestational diabetes mellitus. Clin. Sci. (Lond.). 2006;110:605–609
  58. O’Carroll AM, Selby TL, Palkovits M, Lolait SJ. Distribution of mrna encoding b78/apj, the rat homologue of the human apj receptor, and its endogenous ligand apelin in brain and peripheral tissues. Biochim. Biophys. Acta. 2000;1492:72–80
  59. Lee DK, Cheng R, Nguyen T, Fan T, Kariyawasam AP, Liu Y, et al. Characterization of apelin, the ligand for the apj receptor. J. Neurochem. 2000;74:34–41
  60. Reaux A, De Mota N, Skultetyova I, Lenkei Z, El Messari S, Gallatz K, et al. Physiological role of a novel neuropeptide, apelin, and its receptor in the rat brain. J. Neurochem. 2001;77:1085–1096
  61. Chen MM, Ashley EA, Deng DX, Tsalenko A, Deng A, Tabibiazar R, et al. Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation. 2003;108:1432–1439
  62. Boucher J, Masri B, Daviaud D, Gesta S, Guigne C, Mazzucotelli A, et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology. 2005;146:1764–1771
  63. Sorhede Winzell M, Magnusson C, Ahren B. The apj receptor is expressed in pancreatic islets and its ligand, apelin, inhibits insulin secretion in mice. Regul. Pept. 2005;131:12–17
  64. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature. 2005;436:356–362
  65. Cook KS, Min HY, Johnson D, Chaplinsky RJ, Flier JS, Hunt CR, et al. Adipsin: a circulating serine protease homolog secreted by adipose tissue and sciatic nerve. Science. 1987;237:402–405
  66. Millar CA, Meerloo T, Martin S, Hickson GR, Shimwell NJ, Wakelam MJ, et al. Adipsin and the glucose transporter glut4 traffic to the cell surface via independent pathways in adipocytes. Traffic. 2000;1:141–151
  67. Flier JS, Cook KS, Usher P, Spiegelman BM. Severely impaired adipsin expression in genetic and acquired obesity. Science. 1987;237:405–408
  68. Napolitano A, Lowell BB, Damm D, Leibel RL, Ravussin E, Jimerson DC, et al. Concentrations of adipsin in blood and rates of adipsin secretion by adipose tissue in humans with normal, elevated and diminished adipose tissue mass. Int. J. Obes. Relat. Metab. Disord. 1994;18:213–218
  69. Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, Hansen BC, et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am. J. Physiol. Endocrinol. Metab. 2006;
  70. Monzillo LU, Hamdy O, Horton ES, Ledbury S, Mullooly C, Jarema C, et al. Effect of lifestyle modification on adipokine levels in obese subjects with insulin resistance. Obes. Res. 2003;11:1048–1054
  71. Von Eynatten M, Schneider JG, Hadziselimovic S, Hamann A, Bierhaus A, Nawroth PP, et al. Adipocytokines as a novel target for the anti-inflammatory effect of atorvastatin in patients with type 2 diabetes. Diabetes Care. 2005;28:754–755
  72. Ballantyne GH, Gumbs A, Modlin IM. Changes in insulin resistance following bariatric surgery and the adipoinsular axis: role of the adipocytokines, leptin, adiponectin and resistin. Obes. Surg. 2005;15:692–699
  73. Hsieh CJ, Wang PW, Liu RT, Tung SC, Chien WY, Chen JF, et al. Orlistat for obesity: benefits beyond weight loss. Diabetes Res. Clin. Pract. 2005;67:78–83
  74. Bajaj M, Suraamornkul S, Hardies LJ, Pratipanawatr T, DeFronzo RA. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type ii diabetic patients. Int. J. Obes. Relat. Metab. Disord. 2004;28:783–789
  75. Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J. Clin. Endocrinol. Metab. 2004;89:4312–4319
  76. Tamori Y, Sakaue H, Kasuga M. Rbp4, an unexpected adipokine. Nat. Med. 2006;12:30–31(discussion 31)

PII: S0168-8227(06)00246-4

doi: 10.1016/j.diabres.2006.06.004

Diabetes Research and Clinical Practice
Volume 74, Issue 2, Supplement , Pages S3-S8 , 30 November 2006

Article Tools